Clinical trial · no report yet · Phase 2
WU-KONG6
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
- NCT05712902 ↗
- Active, not recruiting
- Dizal Pharmaceuticals
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Single Arm, Multicenter Study to Evaluate Anti-tumor Activity, Safety, Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Sunvozertinib
- Arms
- Daily dose of Sunvozertinib · Experimental
- Enrollment
- 104
- Primary outcomes
- Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)
- Sponsor
- Dizal Pharmaceuticals
- Start
- Jul 19, 2021
- Primary completion
- Oct 17, 2022
- Results posted
- No
- Registry record
- NCT05712902 · updated Dec 30, 2024
Publications
linked from the registry- Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, Hu Y, Han Z, Song X, Liu A, Tang K, Ding C, Liang L, Wu L, Gao J, Wang J, Cheng Y, Zhou J, He Y, Dong X, Yao Y, Yu Y, Wang H, Sun S, Huang J, Fang J, Li W, Wang L, Ren X, Zhou C, Hu Y, Zhao D, Yang R, Xu F, Huang Y, Pan Y, Cui J, Xu Y, Yang Z, Shi Y. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12. PubMed 38101437